Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats

International Urology and Nephrology

Volumn 42, Issue 1, 2010, Pages 53-56

  Matsumoto, Seiji ^a,b   Hanai, Tadashi ^a,b   Uemura, Hirotsugu ^b  

^a Koushinkai Hospital   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder; Chronic; Function; PDE5 inhibitor; Vardenafil

Indexed keywords

CARBACHOL; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHLORIDE; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CONTRACTION; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ELECTRIC FIELD; ELECTROSTIMULATION; FEMALE; LONG TERM CARE; NONHUMAN; ORGAN WEIGHT; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; IMIDAZOLES; MUSCLE CONTRACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TRIAZINES; URINARY BLADDER;

EID: 77950918374     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9564-7     Document Type: Article

References (15)

1. K Sairam E Kulinskaya TA McNicholas, et al. 2002 Sildenafil influences lower urinary tract symptoms BJU Int 90 836 839 10.1046/j.1464-410X.2002.03040.x 1:CAS:528:DC%2BD3sXjtFWqtg%3D%3D 12460342 (Pubitemid 36693615)
2. KT McVary CG Roehrborn JC Kaminetsky, et al. 2007 Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 1401 1407 10.1016/j.juro.2006.11.037 1:CAS:528:DC%2BD2sXksVantL8%3D 17382741 (Pubitemid 46435965)
3. KT McVary W Monnig JL Camps Jr, et al. 2007 Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 1071 1077 10.1016/j.juro.2006.10.055 1:CAS:528:DC%2BD2sXjtF2hsrY%3D 17296414 (Pubitemid 46216352)
4. CG Stief H Porst D Neuser, et al. 2008 A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 1236 1244 10.1016/j.eururo.2008.01.075 1:CAS:528:DC%2BD1cXotlCqtLw%3D 18281145
5. M Gacci G Del Popolo A Macchiarella, et al. 2007 Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study J Urol 178 2040 2043 10.1016/j.juro.2007.07.048 1:CAS:528:DC%2BD2sXht12rtrvJ 17869296 (Pubitemid 47538622)
6. H Tinel B Stelte-Ludwig J Hutter, et al. 2006 Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 1259 1263 10.1111/j.1464-410X.2006.06501.x 1:CAS:528:DC%2BD2sXktlakuw%3D%3D 16956354 (Pubitemid 44721238)
7. S Filippi A Morelli P Sandner, et al. 2007 Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 1019 1029 10.1210/en.2006-1079 1:CAS:528:DC%2BD2sXitlWnsrY%3D 17138653 (Pubitemid 46272788)
8. S Matsumoto T Hanai H Uemura, et al. 2009 Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model BJU Int 103 987 990 10.1111/j.1464-410X.2008.08185.x 1:CAS:528:DC%2BD1MXksl2qsL8%3D 19021615
9. S Matsumoto P Chichester BA Kogan, et al. 2003 Structural and vascular response of normal and obstructed rabbit whole bladders to distension Urology 62 1129 1133 10.1016/S0090-4295(03)00686-1 14665376 (Pubitemid 37510106)
10. C Foresta A Lana A Cabrelle, et al. 2005 PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans Int J Impot Res 17 377 380 10.1038/sj.ijir.3901325 1:CAS:528:DC%2BD2MXlslGnsLs%3D 15829988 (Pubitemid 41025774)
11. E Miller-Kasprzak PP Jagodziński 2007 Endothelial progenitor cells as a new agent contributing to vascular repair Arch Immunol Ther Exp (Warsz) 55 247 259 10.1007/s00005-007-0027-5 1:CAS:528:DC%2BD2sXhtFWqt7vL (Pubitemid 47262710)
12. K Komori A Tsujimura T Takao, et al. 2008 Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3′, 5′-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells J Sex Med 5 1623 1635 10.1111/j.1743-6109.2008.00772.x 1:CAS:528:DC%2BD1cXpvVyru78%3D 18331270 (Pubitemid 352044419)
13. EC Breen 2007 VEGF in biological control J Cell Biochem 102 1358 1367 10.1002/jcb.21579 1:CAS:528:DC%2BD2sXhsVeit7fE 17979153 (Pubitemid 350223939)
14. Y Qiu P Kraft EC Craig, et al. 2001 Identification and functional study of phosphodiesterases in rat urinary bladder Urol Res 29 388 392 10.1007/s00240-001-0221-6 1:CAS:528:DC%2BD38XhtFShurs%3D 11828991 (Pubitemid 34042184)
15. Y Qiu P Kraft EC Craig, et al. 2002 Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle Urol Res 59 145 149 (Pubitemid 34059337)